Фармакологические взаимодействия психотропных препаратов с анестетиками: риски и особенности периоперационного ведения

Обоснование: проблемы анестезиологического сопровождения пациентов с психическими расстройствами приобретают все большую клиническую значимость в связи с ростом числа хирургических вмешательств у данной категории больных. Фармакологические взаимодействия между психотропными средствами и анестетиками способны оказывать существенное влияние на глубину, продолжительность и безопасность анестезии. Эти аспекты требуют комплексного анализа с позиций современной психофармакологии и анестезиологии. Цель обзора: провести анализ современных исследований, посвященных взаимодействию психофармакологических препаратов с анестетиками, с акцентом на выявление клинически значимых закономерностей и потенциальных рисков в периоперационном периоде. Материал и методы: поиск зарубежных статей проводился в базах данных PsycINFO, PubMed, SciSpace с использованием поискового запроса по ключевым словам: «interactions», «side effects», «anesthesia», «psychopharmacology», «pharmacokinetics» в различных сочетаниях. Русскоязычные статьи были отобраны путем поиска в базе данных eLibrary.ru по ключевым словам: «взаимодействие», «анестетики», «анестезия», «психофармакология». Обсуждение: проведенный анализ современных исследований убедительно демонстрирует, что психофармакологические препараты способны значительно изменять действие анестетиков, создавая как новые терапевтические возможности, так и клинические риски. Исследователи акцентируют внимание на механизмах модификации фармакокинетики путем модуляции активности изоферментов цитохрома P450 и существенных изменениях в нейромедиаторных системах ЦНС. Особого внимания требуют взаимодействия, обладающие высоким риском чрезмерной седации, опасности серотонинового синдрома, а также кардиотоксических эффектов. Заключение: изучение и учет взаимодействий между психофармакологическими препаратами и анестетиками не только повышают безопасность анестезии, но и способствуют улучшению качества медицинской помощи, что особенно важно для уязвимой группы психиатрических пациентов. Дальнейшие исследования в этом направлении позволят разработать еще более точные алгоритмы персонализированного подхода в периоперационном периоде.

1. Shafer SL, Stanski DR. Defining depth of anesthesia. Handb Exp Pharmacol. 2008;(182):409–23.

2. Skibiski J, Patel P, Abdijadid S. Barbiturates. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539731/

3. Krasowski MD. Contradicting a Unitary Theory of General Anesthetic Action: a History of Three Compounds from 1901 to 2010. Bull Anesth Hist. 2006 Jul;21(3):1–passim.

4. Rosenbaum SB, Gupta V, Palacios JL. Ketamine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470357/

5. Solt K, Forman SA. Correlating the clinical actions and molecular mechanisms of general anesthetics. Curr Opin Anaesthesiol. 2007;20(4):300–306.

6. Sproule BA, Naranjo CA, Bremner KE, Hassan PC. Selective Serotonin Reuptake Inhibitors and CNS Drug Interactions. Clin Pharmacokinet. 2020;33:454–471.

7. Singh HK, Saadabadi A. Sertraline. 2023 Feb 13. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31613469.

8. Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024 Jul;11(7):526–535. doi: 10.1016/S2215-0366(24)00133-0 PMID: 38851198.

9. Matsunaga F, Gao L, Huang XP, Saven JG, Roth BL, Liu R. Molecular interactions between general anesthetics and the 5HT2B receptor. J Biomol Struct Dyn. 2015;33(1):211–8.

10. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21.

11. Wu G, Xu H. A synopsis of multitarget therapeutic effects of anesthetics on depression. Eur J Pharmacol. 2023;957:176032.

12. Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, Kaye AD, Viswanath O, Urits I, Boyer AG, Cornett EM, Kaye AM. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol Int. 2021 Aug 5;13(3):387–401. doi: 10.3390/neurolint13030038 PMID: 34449705; PMCID: PMC8395812.

13. Mahdanian AA, Rej S, Bacon SL, Ozdin D, Lavoie KL, Looper K. Serotonergic antidepressants and perioperative bleeding risk: a systematic review. Expert Opin Drug Saf. 2014 Jun;13(6):695–704. doi: 10.1517/14740338.2014.908182 PMID: 24717049.

14. Singh D, Saadabadi A. Venlafaxine. 2024 Feb 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30570984.

15. Komahashi-Sasaki H, Yasui-Furukori N, Sasaki T, Shinozaki M, Hayashi Y, Kato K, Inoue Y, Tsuchimine S, Watanabe T, Sugawara N, Shimoda K. Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression. Ther Drug Monit. 2021 Oct 1;43(5):681–687. doi: 10.1097/FTD.0000000000000854 PMID: 33306568.

16. Papp A, Onton JA. Brain Zaps: An Underappreciated Symptom of Antidepressant Discontinuation. Prim Care Companion CNS Disord. 2021;20(6):18m02311.

17. Howland RH. Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs. J Psychosoc Nurs Ment Health Serv. 2010;48(7):9–12.

18. Hansen D, Fuhring U, Eyrich K. Long-term antidepressive medication an increased anesthetic risk? Anaesthesist. 2008;39(4):205–10.

19. Беккер Р, Быков Ю. Проблематика проведения общей анестезии на фоне приема психофармакотерапии (Часть I). 2018:73.

20. Беккер Р, Быков Ю. Проблематика проведения общей анестезии на фоне приема психофармакотерапии (Часть II). 2018:84.

21. Zorn A, Linn S, Jenkinson M, Neher JO, Safranek S, Kelsberg G. Is ketamine effective and safe for treatment-resistant depression? J Fam Pract. 2021 Apr;70(3):E1–E3. doi: 10.12788/jfp.0176 PMID: 34314342.

22. De Maricourt P, Jay T, Goncalvès P, Lôo H, Gaillard R. Effet antidépresseur de la kétamine : revue de la littérature sur l'utilisation de la kétamine dans la dépression [Ketamine's antidepressant effect: literature review on clinical use]. Encéphale. 2014 Feb;40(1):15–23. French. doi: 10.1016/j.encep.2013.09.001 Epub 2014 Jan 14. PMID: 24434008.

23. Mein N, Mammadli K, Luessi F, Uphaus T. Venlafaxine-induced serotonin syndrome causing bilateral cerebral strokes: a case report. Front Stroke. 2025;3:1529674. doi: 10.3389/fstro.2024.1529674

24. Fazio G, Vernuccio F, Grutta G, Re GL. Drugs to be avoided in patients with long QT syndrome: Focus on the anaesthesiological management. World J Cardiol. 2013;5(4):87–93.

25. Bevan RK, Rose MA, Duggan KA. Evidence for direct interaction of ketamine with alpha 1and beta 2-adrenoceptors. Clin Exp Pharmacol Physiol. 2020;24(12):923–926.

26. Chin KJ, El-Boghdadly K. Mechanisms of action of the erector spinae plane (ESP) block: a narrative review. Can J Anesth. 2021;68:387–408.

27. Leucht C, Huhn M, Leucht S. Amitriptyline versus placebo for major depressive disorder. Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD009138. doi: 10.1002/14651858 PMID: 23235671; PMCID: PMC11299154.

28. Малова АО, Булыгина ИЕ, Никитин ЛН, Андреева АП, Ильина СИ. Использование антидепрессантов в различных популяционных группах. Acta Medica Eurasica. 2019;(4):4–26.

29. Duggal HS. Delirium associated with amitriptyline/fluconazole drug. Gen Hosp Psychiatry. 2006;25(4):297–298.

30. Brueckle MS, Thomas ET, Seide SE, Pilz M, Gonzalez-Gonzalez AI, Dinh TS, Gerlach FM, Harder S, Glasziou PP, Muth C. Amitriptyline's anticholinergic adverse drug reactions-A systematic multiple-indication review and meta-analysis. PLoS One. 2023 Apr 5;18(4):e0284168. doi: 10.1371/journal.pone.0284168 PMID: 37018325; PMCID: PMC10075391.

31. Киреев СС, Бадаква ТЛ, Чуканова ОА. Делирий в послеоперационном периоде (обзор литературы). Вестник новых медицинских технологий. 2019;(2):44–60

32. Чекмарев ГВ, Долгих ВТ. Механизмы кардиотоксического действия амитриптилина. Общая реаниматология. 2011;7(6):24. doi: 10.15360/1813-9779-2011-6-24

33. Navia-Pelaez JM, Dias MTS, Orellano LAA, Campos GP, Alvarez-Leite JI, Campos PP, Capettini LSA. Dual effect of amitriptyline in the control of vascular tone: Direct blockade of calcium channel in smooth muscle cells and reduction of TLR4-dependent NO production in endothelial cells. Eur J Pharmacol. 2022;934:175255.

34. Yip R, Swainson J, Khullar A, McIntyre RS, Skoblenick K. Intravenous ketamine for depression: A clinical discussion reconsidering best practices in acute hypertension management. Front Psychiatry. 2022;13:1017504.

35. Sawynok J, Zinger C. Topical amitriptyline and ketamine for post-herpetic neuralgia and other forms of neuropathic pain. Expert Opin Pharmacother. 2016;17:601–609.

36. Adeyinka A, Patel A, Kondamudi NP. Cholinergic Crisis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. PMID: 29494040.

37. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2021;33(10):2303–2312.

38. Joshi K, Rao S, Mehta S. A Review of Pharmacokinetic and Pharmacodynamic Properties of Quetiapine IR and XR: Insights and Clinical Practice Implications. Cureus. 2025 Jun 18;17(6):e86258. doi: 10.7759/cureus.86258 PMID: 40688841; PMCID: PMC12272296.

39. Arango C, Bobes J, Garcia-Garcia M, Rejas J. Quetiapine XR in schizophrenia: efficacy and tolerability in clinical practice. Int Clin Psychopharmacol. 2013;28(5):237–244.

40. Maan JS, Ershadi M, Khan I, et al. Quetiapine. [Updated 2023 Aug 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459145/

41. Fukushi R, Nomura Y, Katashima M, Komatsu K, Sato Y, Takada A. Approach to Evaluating QT Prolongation of Quetiapine Fumarate in Late Stage of Clinical Development Using Concentration-QTc Modeling and Simulation in Japanese Patients With Bipolar Disorder. Clin Ther. 2020 Aug;42(8):1483–1493.e1. doi: 10.1016/j.clinthera.2020.06.002 Epub 2020 Aug 11. PMID: 32792252.

42. Poole KA, Weber N, Aziz M. Case report: quetiapine and refractory hypotension during general anesthesia in the operating room. Anesth Analg. 2013;117(3):641–643.

43. Zaccara G, Franco V. Pharmacokinetic interactions between antiseizure and psychiatric medications. Curr Neuropharmacol. 2023;21(8):1666–1690.

44. Spina E, Barbieri MA, Cicala G, de Leon J. Clinically relevant interactions between atypical antipsychotics and anti-infective agents. Pharmaceuticals (Basel). 2020;13(12):439.

45. Veraart JKE, Smith-Apeldoorn SY, Bakker IM, Visser BAE, Kamphuis J, Schoevers RA, Touw DJ. Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. Int J Neuropsychopharmacol. 2021 Oct 23;24(10):808–831. doi: 10.1093/ijnp/pyab039 PMID: 34170315; PMCID: PMC8538895.

46. Amiaz R, Saporta R, Noy A, Berkenstadt H, Weiser M. Can quetiapine prolong the antidepressant effect of ketamine?: a 5-year follow-up study. J Clin Psychopharmacol. 2021;41(6):673–675.

47. Tayyab S, Feroz SR. Serum albumin: clinical significance of drug binding and development as drug delivery vehicle. In: Advances in Protein Chemistry and Structural Biology. 2021;123:193–218.

48. Jones NC, Reddy M, Anderson P, Salzberg MR, O'Brien TJ, Pinault D. Acute administration of typical and atypical antipsychotics reduces EEG gamma power, but only the preclinical compound LY379268 reduces the ketamine-induced rise in gamma power. Int J Neuropsychopharmacol. 2012;15(5):657–668.

49. Josephs CA, Shaffer VO, Kucera WB. Impact of Mental Health on General Surgery Patients and Strategies to Improve Outcomes. Am Surg. 2023 Jun;89(6):2636– 2643. doi: 10.1177/00031348221109469 Epub 2022 Jun 22. PMID: 35730505.

50. Quesada Salas AH. Metoclopramida: usos y reacciones adversas. LATAM Rev Latinoam Cienc Soc Humanid. 2023;4(2).

51. Santa C, Rodrigues D, Coelho JF, Anjo SI, Mendes VM, Bessa-Neto D, Dunn MJ, Cotter D, Baltazar G, Monteiro P, Manadas B. Chronic treatment with D2-antagonist haloperidol leads to inhibitory/excitatory imbalance in striatal D1-neurons. Transl Psychiatry. 2023 Oct 6;13(1):312. doi: 10.1038/s41398-023-02609-w PMID: 37803004; PMCID: PMC10558446.

52. Estave PM, Spodnick MB, Karkhanis AN. KOR Control over Addiction Processing: An Exploration of the Mesolimbic Dopamine Pathway. Handb Exp Pharmacol. 2022;271:351–377. doi: 10.1007/164_2020_421 PMID: 33301050; PMCID: PMC8192597.

53. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41.

54. Whitlock EL, Vannucci A, Avidan MS. Postoperative delirium. Minerva Anestesiol. 2011 Apr;77(4):448–56. PMID: 21483389; PMCID: PMC3615670.

55. Guani L, Arshoun A, Murdock A, Espiridion E. Haloperidol-Induced Laryngeal Dystonia: A Case Report on an Antipsychotic-Associated Airway Emergency. Cureus. 2024;16(11),e74761. doi: 10.7759/cureus.74761

56. Ottens TH, van den Boogaard M, van Munster BC. Should ICU delirium be routinely treated with haloperidol? No!, Intensive Crit Care Nurs. 2025;5(32). doi: 10.1016/j.iccn.2025.104211

57. Dar PM, Kaur S, Boddeda J, Wani SM. Haloperidol induced sudden cardiac arrest—report of a very rare case and review of literature. Case Rep Psychiatry. 2020;2020:1836716. doi: 10.1155/2020/1836716

58. Garcia MC, Anderson M, Li M, Zewdu M, Schneider T, Matos-Silva J, Ramnarine G, Rong K, Mbuagbaw L, Holbrook A. Major adverse cardiac events with haloperidol: A meta-analysis. PLoS One. 2025 Jun 25;20(6):e0326804. doi: 10.1371/journal.pone.0326804 PMID: 40561150; PMCID: PMC12194150.

59. Wood M. Pharmacokinetic drug interactions in anaesthetic practice. Clin Pharmacokinet. 1991 Oct;21(4):285–307. doi: 10.2165/00003088-199121040-00005 PMID: 1760901.

60. Franks NP. General anaesthesia: from molecular targets to neuronal pathways of sleep and arousal. Nat Rev Neurosci. 2008 May;9(5):370–86. doi: 10.1038/nrn2372 PMID: 18425091

61. Hollinger A, Rüst CA, Riegger H, Gysi B, Tran F, Brügger J, Huber J, Toft K, Surbeck M, Schmid HR, Rentsch K, Steiner L, Siegemund M. Ketamine vs. haloperidol for prevention of cognitive dysfunction and postoperative delirium: A phase IV multicentre randomised placebo-controlled double-blind clinical trial. J Clin Anesth. 2021 Feb;68:110099. doi: 10.1016/j.jclinane.2020.110099 Epub 2020 Oct 22. PMID: 33120302.

62. Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013;19(6):370–380.

63. Rahman M, Awosika AO, Nguyen H. Valproic Acid. [Updated 2024 Mar 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559112/

64. Olsen KB, Taubøll E, Gjerstad L. Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults. Acta Neurol Scand Suppl. 2007;187:51–54.

65. Mishra MK, Kukal S, Paul PR, Bora S, Singh A, Kukreti S, Saso L, Muthusamy K, Hasija Y, Kukreti R. Insights into Structural Modifications of Valproic Acid and Their Pharmacological Profile. Molecules. 2021 Dec 24;27(1):104. doi: 10.3390/molecules27010104 PMID: 35011339; PMCID: PMC8746633.

66. Methaneethorn J. A systematic review of population pharmacokinetics of valproic acid. Br J Clin Pharmacol. 2018 May;84(5):816–834. doi: 10.1111/bcp.13510 Epub 2018 Feb 28. PMID: 29328514; PMCID: PMC5903263.

67. Wong YJ, Fan J, Wan A, Mihic T, Gnyra M. Valproic Acid-Associated Hyperammonemia: A Systematic Review. J Clin Psychopharmacol. 2023 May–Jun 01;43(3):283–294. doi: 10.1097/JCP.0000000000001689 PMID: 37126830.

68. Golub A, Ordak M, Nasierowski T, Bujalska-Zadrozny M. Advanced Biomarkers of Hepatotoxicity in Psychiatry: A Narrative Review and Recommendations for New Psychoactive Substances. Int J Mol Sci. 2023 May 28;24(11):9413. doi: 10.3390/ijms24119413 PMID: 37298365; PMCID: PMC10253383.

69. Abdallah C. Considerations in perioperative assessment of valproic acid coagulopathy. J Anaesthesiol Clin Pharmacol. 2014 Jan;30(1):7–9. doi: 10.4103/0970-9185.125685 PMID: 24574585; PMCID: PMC3927296

70. Du Z, Wang J, Nie G, Li Y, Liu M. Risk factors for thrombocytopenia associated with intravenous valproic acid therapy in pediatric patients undergoing neurosurgical operations. Sci Rep. 2025 Apr 21;15(1):13675. doi: 10.1038/s41598-025-98870-8 PMID: 40258981; PMCID: PMC12012216.

71. Shnayder NA, Grechkina VV, Khasanova AK, Bochanova EN, Dontceva EA, Petrova MM, Asadullin AR, Shipulin GA, Altynbekov KS, Al-Zamil M, Nasyrova RF. Therapeutic and Toxic Effects of Valproic Acid Metabolites. Metabolites. 2023 Jan 16;13(1):134. doi: 10.3390/metabo13010134 PMID: 36677060; PMCID: PMC9862929.

72. Hizli Sayar G, Eryılmaz G, Şemieoğlu S, Özten E, Gül I. Influence of valproate on the required dose of propofol for anesthesia during electroconvulsive therapy of bipolar affective disorder patients. Neuropsychiatr Dis Treat. 2014;10:433–438.

73. Ouchi K. The number and kind of antiepileptics affect propofol dose requirement for anesthesia: observational study. Odontology. 2020 Jan;108(1):102–108. doi: 10.1007/s10266-019-00457-z PMID: 31562580.

74. Aguilera L, Calvo R, Garcia RC. Interaction between thiopentone and sodium valproate: an in vitro and in vivo study. Br J Anaesth. 2020;58(12):1380–1383.

75. Sixto-López Y, Bello M, Correa-Basurto J. Exploring the inhibitory activity of valproic acid against the HDAC family using an MMGBSA approach. J Comput Aided Mol Des. 2020 Aug;34(8):857–878. doi: 10.1007/s10822-020-00304-2 Epub 2020 Mar 16. PMID: 32180123.

76. Jo S, Bean BP. Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381–7. doi: 10.1124/mol.113.090472 Epub 2013 Dec 6. PMID: 24319110; PMCID: PMC3913360.

77. Yip VLM, Pertinez H, Meng X, Maggs JL, Carr DF, Park BK, Marson AG, Pirmohamed M. Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine. Br J Clin Pharmacol. 2021 Jun;87(6):2572–2588. doi: 10.1111/bcp.14667 Epub 2020 Dec 14. PMID: 33217013; PMCID: PMC8247401.

78. Fuhr LM, Marok FZ, Hanke N, Selzer D, Lehr T. Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach. Pharmaceutics. 2021 Feb 17;13(2):270. doi: 10.3390/pharmaceutics13020270 PMID: 33671323; PMCID: PMC7922031.

79. Al Khalili Y, Sekhon S, Jain S. Carbamazepine Toxicity. [Updated 2023 Jul 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507852/

80. Prakash S, Bhatia PS, Raheja SG, Pawar M. Carbamazepine-induced hyponatremia. Br J Anaesth. 2016;117(Suppl):e13266. DOI: https://doi.org/10.1093/bja/el_13266

81. Yasir M, Mechanic OJ. Syndrome of Inappropriate Antidiuretic Hormone Secretion. [Updated 2023 Mar 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507777/

82. Harbell MW, Dumitrascu C, Bettini L, Yu S, Thiele CM, Koyyalamudi V. Anesthetic Considerations for Patients on Psychotropic Drug Therapies. Neurol Int. 2021 Nov 29;13(4):640–658. doi: 10.3390/neurolint13040062 PMID: 34940748; PMCID: PMC8708655.

83. Lineham A, Avila-Quintero VJ, Bloch MH, Dwyer JB. The relationship between acute dissociative effects induced by ketamine and treatment response in adolescent patients with treatment-resistant depression. J Child Adolesc Psychopharmacol. 2023;33(1):20–26.

84. Jia L, Eroglu TE, Wilders R, Verkerk AO, Tan HL. Carbamazepine Increases the Risk of Sudden Cardiac Arrest by a Reduction of the Cardiac Sodium Current. Front Cell Dev Biol. 2022 Jun 3;10:891996. doi: 10.3389/fcell.2022.891996 PMID: 35721495; PMCID: PMC9204209.

85. Sarai SK, Mekala HM, Lippmann S. Lithium Suicide Prevention: A Brief Review and Reminder. Innov Clin Neurosci. 2018 Nov 1;15(11–12):30–32. PMID: 30834169; PMCID: PMC6380616.

86. Sánchez Triviño CA, Landinez MP, Duran S, Gomez MP, Nasi E. Modulation of Gq/PLC-Mediated Signaling by Acute Lithium Exposure. Front Cell Neurosci. 2022;1. doi: 10.3389/fncel.2022.838939

87. Ferensztajn-Rochowiak E, Rybakowski JK. LongTerm Lithium Therapy: Side Effects and Interactions. Pharmaceuticals (Basel). 2023 Jan 3;16(1):74. doi: 10.3390/ph16010074 PMID: 36678571; PMCID: PMC9867198.

88. Gitlin, M., Bauer, M. Lithium: current state of the art and future directions. Int J Bipolar Disord. 2020;12(40). https://doi.org/10.1186/s40345-024-00362-7

89. Acharya S, Siddiqui AH, Anwar S, Habib S, Anwar S. Lithium-induced Cardiotoxicity: A Rare Clinical Entity. Cureus. 2020 Mar 16;12(3):e7286. doi: 10.7759/cureus.7286 PMID: 32300505; PMCID: PMC7159167.

90. Heidari A, Mohamadizade N, Hasanzade A, Fazlekhoda M. Chronic Lithium-Induced Cardiotoxicity: A Case Report and Lessons for Clinical Practice. Case Rep Med. 2025 Jun 26;2025:5599471. doi: 10.1155/carm/5599471 PMID: 40620862; PMCID: PMC12226198.

91. Menegueti MG, Basile-Filho A, Martins-Filho OA, Auxiliadora-Martins M. Severe arrhythmia after lithium intoxication in a patient with bipolar disorder admitted to the intensive care unit. Indian J Crit Care Med. 2012 Apr;16(2):109–11. doi: 10.4103/0972-5229.99134 PMID: 22988367; PMCID: PMC3439772.

92. Iorgoveanu C, Zaghloul A, Donisan T, Valentin Balanescu D, Balakumaran K, Mihai Balanescu S. Atypical Arrhythmia Associated with Lithium Therapy: When to Expect the Unexpected? Acta Cardiol Sin. 2019 Mar;35(2):179–182. doi: 10.6515/ACS.201903_35(2).20181001A PMID: 30930565; PMCID: PMC6434419.

93. Baldessarini RJ, Tondo L, Viguera AC. Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications. Bipolar Disord. 2017;1(1):17–24.

94. Aroke EN, Robinson AN, Wilbanks BA. Perioperative considerations for patients with major depressive disorder undergoing surgery. J Perianesth Nurs. 2021;35(2):112–119.

95. Ping L, Jiarui Z, Fangyu S, Zong-An L. Can haloperidol prophylaxis reduce the incidence of delirium in critically ill patients in intensive care units? A systematic review and meta-analysis. Heart Lung. 2020;49(3):265272. doi: 10.1016/j.hrtlng.2020.01.010

96. Malhi GS, Bell E, Outhred T, Berk M. Lithium therapy and its interactions. Aust Prescr. 2020 Jun;43(3):91–93. doi: 10.18773/austprescr.2020.024 PMID: 32675910; PMCID: PMC7358048.

97. Hassan S, Khalid F, Alirhayim Z, Amer S. Lithium toxicity in the setting of nonsteroidal anti-inflammatory medications. Case Rep Nephrol. 2013;2013:839796. doi: 10.1155/2013/839796 PMID: 24558630; PMCID: PMC3914168.

98. Liu JR, Han XH, Yuki K, Soriano SG. Ketamine modulates disrupted in schizophrenia-1/glycogen synthase kinase-3β interaction. Front Mol Neurosci. 2024;17:1342233.

99. Price JB, Yates CG, Morath BA, Van De Wakker SK, Yates NJ, Butters K, Frye MA, McGee SL, Tye SJ. Lithium augmentation of ketamine increases insulin signaling and antidepressant-like active stress coping in a rodent model of treatment-resistant depression. Transl Psychiatry. 2021 Nov 25;11(1):598. doi: 10.1038/s41398-021-01716-w PMID: 34824208; PMCID: PMC8617175.